tbuckley/cabot-search huggingface dataset:
Eutherian-Specific Gene TRIML2 Attenuates Inflammation in the Evolution of Placentation
Authors: Xuzhe Zhang, Mihaela Pavlicev, Helen N Jones, Louis J Muglia
Journal: Molecular Biology and Evolution (2019)

Abstract Evolution of highly invasive placentation in the stem lineage of eutherians and subsequent extension of pregnancy set eutherians apart from other mammals, that is, marsupials with short-lived placentas, and oviparous monotremes. Recent studies suggest that eutherian implantation evolved from marsupial attachment reaction, an inflammatory process induced by the direct contact of fetal placenta with maternal endometrium after the breakdown of the shell coat, and shortly before the onset of parturition. Unique to eutherians, a dramatic downregulation of inflammation after implantation prevents the onset of premature parturition, and is critical for the maintenance of gestation. This downregulation likely involved evolutionary changes on maternal as well as fetal/placental side. Tripartite-motif family-like2 (TRIML2) only exists in eutherian genomes and shows preferential expression in preimplantation embryos, and trophoblast-derived structures, such as chorion and placental disc. Comparative genomic evidence supports that TRIML2 originated from a gene duplication event in the stem lineage of Eutheria that also gave rise to eutherian TRIML1. Compared with TRIML1, TRIML2 lost the catalytic RING domain of E3 ligase. However, only TRIML2 is induced in human choriocarcinoma cell line JEG3 with poly(I:C) treatment to simulate inflammation during viral infection. Its knockdown increases the production of proinflammatory cytokines and reduces trophoblast survival during poly(I:C) stimulation, while its overexpression reduces proinflammatory cytokine production, supporting TRIML2’s role as a regulatory inhibitor of the inflammatory pathways in trophoblasts. TRIML2’s potential virus-interacting PRY/SPRY domain shows significant signature of selection, suggesting its contribution to the evolution of eutherian-specific inflammation regulation during placentation.
P1.01-84 Interaction of Lorlatinib with CYP2B6, CYP2C9, UGT, and P-gp Probe Drugs in Patients with Advanced Non-Small Cell Lung Cancer
Authors: J. Chen, A. Bearz, D. Kim, H. Mamdani, J. Bauman, R. Chiari, S. Ou, B. Solomon, R. Soo, E. Felip, A. Shaw, J. Clancy, K. Lee, M. O'Gorman, C. Tanski, Y. Pithavala
Journal: Journal of Thoracic Oncology (2019)
P1.14-29 Disrupting the Paradigm: Partnering with Oncogene-Focused Patient Groups to Propel Research
Authors: J. Freeman-Daily, B. Addario, C. Barton, U. Basu Roy, S. Blam, I. Elkins, J. Feldman, A. Figueras, R. Hanlon, M. Horn, P. Jänne, C. Lovly, A. Moore, T. Ng, A. Sable-Hunt, S. Shaw, R. Doebele
Journal: Journal of Thoracic Oncology (2019)
Therapeutic superiority of a TCR-like antibody to an intracellular WT1 oncogene peptide compared with the tyrosine kinase inhibitor imatinib in a mouse model of Philadelphia chromosome positive (Ph+) ALL.
Authors: Leonid Dubrovsky, Elliott Joseph Brea, Nicholas J Veomett, Tao Dao, Su Yan, Cheng Liu, David A. Scheinberg
Journal: Journal of Clinical Oncology (2013)

3047 Background: Acute and chronic leukemias demonstrate significantly increased expression of the Wilms tumor gene 1 (WT1) product, including CD34 + CML stem cells, making WT1 an attractive therapeutic target. However, WT1 protein is intracellular and currently un-druggable. ESKM is a fully human IgG1 antibody that targets a 9 amino acid sequence (RMF) of the protein WT1 in the context of HLA-A0201. Methods: BV173 is an HLA-A0201 positive Ph+ ALL cell line. It over-expresses WT1 and binds strongly to ESKM. We evaluated the in vitro and in vivo efficacy of ESKM in combination with TKIs. Antibody-dependent cell-mediated cytotoxicity (ADCC) was evaluated in vitro by chromium release assay, utilizing human PBMC effectors. In vivo tumor growth was assessed in NSG mice bearing disseminated luciferase tagged BV173 with bioluminescence imaging and flow cytometry of the bone marrow after sacrifice. Imatinib was used at maximum tolerated doses for these mice as determined in pilot studies. Results: The addition of imatinib in vitro did not affect the ability of ESKM to perform ADCC. The BV173 engrafted NSG mice treated with ESKM with and without TKIs showed tumor regression one week after beginning therapy, clearing leukemia from the liver and spleen. Mice relapsed primarily in the bone marrow, with increasing luciferase signal after two weeks of therapy. Compared to untreated control animals, after 5 weeks of therapy, imatinib alone only reduced tumor growth by 45%; ESKM alone reduced growth by 81%, and the combination of ESKM and imatinib reduced growth by more than 95%. Flow cytometry of cells remaining after treatment showed binding of ESKM, suggesting escape was not due to down regulation of the epitope. Conclusions: In this mouse model of Ph+ ALL, ESKM antibody therapy is superior to imatinib and the combination of both modalities is additive. This antibody is efficacious in vitro and in vivo against WT1 overexpressing leukemias, in context of HLA-A0201. This combination holds promise as a therapy for leukemias in patients who are HLA-A0201 positive, with the potential of improved cytoreduction in patients with Ph+ leukemias.
P2.17-02 Survival in Performance Status 3 Non-Small Cell Lung Cancer Patients Receiving Radical Radiotherapy
Authors: R. Behrouzi, N. Bayman, M. Harris, A. Salem, A. Hudson, C. Chan, C. Faivre-Finn, D. Cobben, H. Sheikh, J. Coote, L. Pemberton, D. Woolf
Journal: Journal of Thoracic Oncology (2019)
P2.14-41 Risk Factors for Brain Metastasis in Patients with EGFR Mutant Non-Small Cell Lung Cancer
Authors: T. Tozuka, M. Seike, Y. Murata, T. Sugano, S. Nakamichi, Y. Minegishi, R. Noro, T. Hirose, K. Kubota, A. Gemma
Journal: Journal of Thoracic Oncology (2019)
Nutrient mTORC1 signaling underpins regulatory T cell control of immune tolerance
Authors: Mytrang H. Do, Xinxin Wang, Xian Zhang, Chun Chou, Briana G. Nixon, Kristelle J. Capistrano, Min Peng, Alejo Efeyan, David M. Sabatini, Ming O. Li
Journal: The Journal of Experimental Medicine (2019)

Foxp3+ regulatory T (T reg) cells are pivotal regulators of immune tolerance, with T cell receptor (TCR)–driven activated T reg (aT reg) cells playing a central role; yet how TCR signaling propagates to control aT reg cell responses remains poorly understood. Here we show that TCR signaling induces expression of amino acid transporters, and renders amino acid–induced activation of mTORC1 in aT reg cells. T reg cell–specific ablation of the Rag family small GTPases RagA and RagB impairs amino acid–induced mTORC1 signaling, causing defective amino acid anabolism, reduced T reg cell proliferation, and a rampant autoimmune disorder similar in severity to that triggered by T reg cell–specific TCR deficiency. Notably, T reg cells in peripheral tissues, including tumors, are more sensitive to Rag GTPase–dependent nutrient sensing. Ablation of RagA alone impairs T reg cell accumulation in the tumor, resulting in enhanced antitumor immunity. Thus, nutrient mTORC1 signaling is an essential component of TCR-initiated T reg cell reprogramming, and Rag GTPase activities may be titrated to break tumor immune tolerance.
P1.16-30 Impact of Patient TKI Copayments on Insurance Expenditure in Advanced EGFR or ALK Positive Non-Small Cell Lung Cancer (NSCLC)
Authors: B. Haddock Lobo Goulart, S. Chennupati, K. Egan, C. Fedorenko, S. Ramsey
Journal: Journal of Thoracic Oncology (2019)
Using routine blood parameters to anticipate clinical outcomes in invasive aspergillosis
Authors: L. Pang, X. Zhao, B.L. Dickens, J.T. Lim, A.R. Cook, M.G. Netea, J.P. Donnelly, R. Herbrecht, E.M. Johnson, J.A. Maertens, B.J. Kullberg, P.F. Troke, K.A. Marr, L.Y.A. Chai
Journal: Clinical Microbiology and Infection (2019)
Regulation of RUNX1 Transcriptional Function by GATA-1 Kinase Recruitment: A Novel Pathway for Megakaryocytic Gene Regulation.
Authors: Kamaleldin E. Elagib, Ivailo S. Mihaylov, Lorrie L. Delehanty, Sara L. Gonias, Jill F. Caronia, Adam N. Goldfarb
Journal: Blood (2006)
MA13.07 Phase I/II Study of Carboplatin Plus Weekly Nab-Paclitaxel in Aged ≥75 Patients with Squamous-Cell Lung Cancer: TORG1322
Authors: Y. Zenke, S. Niho, S. Umemura, M. Ishihara, R. Ochiai, N. Nogami, Y. Hosomi, T. Shimokawa, T. Tokito, Y. Goto, Y. Miura, H. Saito, N. Hida, S. Ikeda, H. Tanaka, N. Furuya, T. Misumi, Y. Ohe, H. Okamoto
Journal: Journal of Thoracic Oncology (2019)
Anti-inflammatory mechanisms of the novel cytokine interleukin-38 in allergic asthma
Authors: Xiaoyu Sun, Tianheng Hou, Edwin Cheung, Tiffany Nga-Teng Iu, Victor Wai-Hou Tam, Ida Miu-Ting Chu, Miranda Sin-Man Tsang, Paul Kay-Sheung Chan, Christopher Wai-Kei Lam, Chun-Kwok Wong
Journal: Cellular and Molecular Immunology (2019)

Abstract We elucidated the anti-inflammatory mechanisms of IL-38 in allergic asthma. Human bronchial epithelial cells and eosinophils were cocultured upon stimulation with the viral RLR ligand poly (I:C)/LyoVec or infection-related cytokine TNF-α to induce expression of cytokines/chemokines/adhesion molecules. House dust mite (HDM)-induced allergic asthma and humanized allergic asthma NOD/SCID murine models were established to assess anti-inflammatory mechanisms in vivo. IL-38 significantly inhibited induced proinflammatory IL-6, IL-1β, CCL5, and CXCL10 production, and antiviral interferon-β and intercellular adhesion molecule-1 expression in the coculture system. Mass cytometry and RNA-sequencing analysis revealed that IL-38 could antagonize the activation of the intracellular STAT1, STAT3, p38 MAPK, ERK1/2, and NF-κB pathways, and upregulate the expression of the host defense-related gene POU2AF1 and anti-allergic response gene RGS13 . Intraperitoneal injection of IL-38 into HDM-induced allergic asthma mice could ameliorate airway hyperreactivity by decreasing the accumulation of eosinophils in the lungs and inhibiting the expression of the Th2-related cytokines IL-4, IL-5, and IL-13 in the bronchoalveolar lavage fluid (BALF) and lung homogenates. Histological examination indicated lung inflammation was alleviated by reductions in cell infiltration and goblet cell hyperplasia, together with reduced Th2, Th17, and innate lymphoid type 2 cell numbers but increased proportions of regulatory T cells in the lungs, spleen, and lymph nodes. IL-38 administration suppressed airway hyperreactivity and asthma-related IL-4 and IL-5 expression in humanized mice, together with significantly decreased CCR3 + eosinophil numbers in the BALF and lungs, and a reduced percentage of human CD4 + CRTH2 + Th2 cells in the lungs and mediastinal lymph nodes. Together, our results demonstrated the anti-inflammatory mechanisms of IL-38 and provided a basis for the development of a regulatory cytokine-based treatment for allergic asthma.
Abstract 13923: Myocardial Afadin is Essential for Maintaining Cardiac Function Against Mechanical Stress-Induced, but Not Pharmacological Stimulation-Mediated, Pressure Overload
Authors: Hisakazu Ogita, Dimitar P Zankov
Journal: Circulation (2017)

Pressure overload, which usually occurs in hypertension and valvular heart diseases, induces cardiac hypertrophy that often ends in heart failure. The molecular mechanisms of this process are not r...
A rapid triage test for active pulmonary tuberculosis in adult patients with persistent cough
Authors: Rushdy Ahmad, Liangxia Xie, Margaret Pyle, Marta F. Suarez, Tobias Broger, Dan Steinberg, Shaali M. Ame, Marilla G. Lucero, Matthew J. Szucs, Melanie MacMullan, Frode S. Berven, Arup Dutta, Diozele M. Sanvictores, Veronica L. Tallo, Robert Bencher, Dominic P. Eisinger, Usha Dhingra, Saikat Deb, Said M. Ali, Saurabh Mehta, Wafaie W. Fawzi, Ian D. Riley, Sunil Sazawal, Zul Premji, Robert Black, Christopher J. L. Murray, Bill Rodriguez, Steven A. Carr, David R. Walt, Michael A. Gillette
Journal: Science Translational Medicine (2019)

A blood protein signature discriminates active tuberculosis (TB) from other TB-like disease in adults regardless of HIV status.
P1.16-12 An Analysis of Healthcare Use and the Cost Associated to End-of-Life Care of Lung Cancer Patients in a Spanish Hospital
Authors: J.L. Cruz, M. Provencio, E. Menasalvas, C. Parejo, F. Martínez-Ruíz, J.C. Sánchez-González, R. Gómez-Bravo, A. Ramos Martín-Vegue, A. Royuela, A. Rodríguez-González
Journal: Journal of Thoracic Oncology (2019)
P2.01-80 Clinical Outcomes in Advanced EGFR-Mutant NSCLC Patients Treated with First-Generation EGFR TKIs Followed by Subsequent Osimertinib
Authors: Y. Yao, J. Cheng, J. Kang, X. Li, H. Chen, Q. Zhou, C. Xu, X. Zhang, J. Su, H. Yan, Y. Wu, J. Yang
Journal: Journal of Thoracic Oncology (2019)
EP1.01-61 iSEND Model as a Predictor of Efficacy in Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer: Fukushima Cohort
Authors: N. Okabe, H. Mine, H. Takagi, M. Watanabe, S. Muto, T. Hasegawa, Y. Shio, W. Park, G. Lopes, H. Suzuki
Journal: Journal of Thoracic Oncology (2019)
Abstract 16833: Aberrant Intracellular and Exosomal miRNA Expression in a Human iPSC Derived Cardiomyocyte Model of Left Ventricular Hypertrophy
Authors: Amy Turner, Praful Aggarwal, Andrea Matter, Rachel Lorier, Steven C Hunt, Cora E Lewis, Donna K Arnett, C C Gu, Ulrich Broeckel
Journal: Circulation (2017)

Left ventricular hypertrophy (LVH) is a risk factor for cardiovascular disease. There is increasing evidence that intracellular miRNAs play a role in the pathogenesis of LVH. In addition, extracell...
Suppression of Cdc37 Induces BTZ Resistance through XBP1s Mediated Plasma Cell Immaturation in Multiple Myeloma
Authors: Meirong Zang, Lanting Liu, Fengyan Jin, Jiaojiao Guo, An Gang, Xiaoqi Qin, Tao Zhu, Shuhui Deng, Zhang Shuaishuai, Mu Hao, Xiaoyan Feng, Yan Xu, Wen Zhou, Lugui Qiu
Journal: Blood (2017)
MA05.07 Efficacy and Safety of Re-Treatment with Tremelimumab and Durvalumab Within the NIBIT-MESO-1 Study
Authors: L. Calabro', G. Rossi, A. Morra, A.M. Di Giacomo, G. Amato, C. Rosati, O. Cutaia, M.G. Daffinà, D. Giannarelli, M. Maio
Journal: Journal of Thoracic Oncology (2019)
P1.12-23 DLL3 Is a Predictive Marker of Sensitivity to Adjuvant Chemotherapy for High-Grade Neuroendocrine Tumors
Authors: H. Ogawa, Y. Sakai, W. Nishio, Y. Fujibayashi, M. Nishikubo, Y. Nishioka, S. Tane, Y. Kitamura, T. Sudo, Y. Sakuma, M. Yoshimura
Journal: Journal of Thoracic Oncology (2019)
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
Authors: G. Aaron Hobbs, Nicole M. Baker, Anne M. Miermont, Ryan D. Thurman, Mariaelena Pierobon, Timothy H. Tran, Andrew O. Anderson, Andrew M. Waters, J. Nathaniel Diehl, Bjoern Papke, Richard G. Hodge, Jennifer E. Klomp, Craig M. Goodwin, Jonathan M. DeLiberty, Junning Wang, Raymond W.S. Ng, Prson Gautam, Kirsten L. Bryant, Dominic Esposito, Sharon L. Campbell, Emanuel F. Petricoin, Dhirendra K. Simanshu, Andrew J. Aguirre, Brian M. Wolpin, Krister Wennerberg, Udo Rudloff, Adrienne D. Cox, Channing J. Der
Journal: Cancer Discovery (2019)

Abstract Allele-specific signaling by different KRAS alleles remains poorly understood. The KRASG12R mutation displays uneven prevalence among cancers that harbor the highest occurrence of KRAS mutations: It is rare (∼1%) in lung and colorectal cancers, yet relatively common (∼20%) in pancreatic ductal adenocarcinoma (PDAC), suggesting context-specific properties. We evaluated whether KRASG12R is functionally distinct from the more common KRASG12D- or KRASG12V-mutant proteins (KRASG12D/V). We found that KRASG12D/V but not KRASG12R drives macropinocytosis and that MYC is essential for macropinocytosis in KRASG12D/V- but not KRASG12R-mutant PDAC. Surprisingly, we found that KRASG12R is defective for interaction with a key effector, p110α PI3K (PI3Kα), due to structural perturbations in switch II. Instead, upregulated KRAS-independent PI3Kγ activity was able to support macropinocytosis in KRASG12R-mutant PDAC. Finally, we determined that KRASG12R-mutant PDAC displayed a distinct drug sensitivity profile compared with KRASG12D-mutant PDAC but is still responsive to the combined inhibition of ERK and autophagy. Significance: We determined that KRASG12R is impaired in activating a key effector, p110α PI3K. As such, KRASG12R is impaired in driving macropinocytosis. However, overexpression of PI3Kγ in PDAC compensates for this deficiency, providing one basis for the prevalence of this otherwise rare KRAS mutant in pancreatic cancer but not other cancers. See related commentary by Falcomatà et al., p. 23. This article is highlighted in the In This Issue feature, p. 1
EP1.09-18 Comparison of Sample Types with Success Rates of Next-Generation Sequencing
Authors: K. Yamane, T. Sakamoto, Y. Terutya, M. Yanai, N. Kinosita, K. Yamaguchi, H. Makino, M. Kodani, T. Igishi, A. Yamasaki
Journal: Journal of Thoracic Oncology (2019)
Stress related disorders and subsequent risk of life threatening infections: population based sibling controlled cohort study
Authors: Huan Song, Katja Fall, Fang Fang, Helga Erlendsdóttir, Donghao Lu, David Mataix-Cols, Lorena Fernández de la Cruz, Brian M. D’Onofrio, Paul Lichtenstein, Magnús Gottfreðsson, Catarina Almqvist, Unnur A Valdimarsdóttir
Journal: BMJ (2019)

Abstract Objective To assess whether severe psychiatric reactions to trauma and other adversities are associated with subsequent risk of life threatening infections. Design Population and sibling matched cohort study. Setting Swedish population. Participants 144 919 individuals with stress related disorders (post-traumatic stress disorder (PTSD), acute stress reaction, adjustment disorder, and other stress reactions) identified from 1987 to 2013 compared with 184 612 full siblings of individuals with a diagnosed stress related disorder and 1 449 190 matched individuals without such a diagnosis from the general population. Main outcome measures A first inpatient or outpatient visit with a primary diagnosis of severe infections with high mortality rates (ie, sepsis, endocarditis, and meningitis or other central nervous system infections) from the Swedish National Patient Register, and deaths from these infections or infections of any origin from the Cause of Death Register. After controlling for multiple confounders, Cox models were used to estimate hazard ratios of these life threatening infections. Results The average age at diagnosis of a stress related disorder was 37 years (55 541, 38.3% men). During a mean follow-up of eight years, the incidence of life threatening infections per 1000 person years was 2.9 in individuals with a stress related disorder, 1.7 in siblings without a diagnosis, and 1.3 in matched individuals without a diagnosis. Compared with full siblings without a diagnosis of a stress related disorder, individuals with such a diagnosis were at increased risk of life threatening infections (hazard ratio for any stress related disorder was 1.47 (95% confidence intervals1.37 to 1.58) and for PTSD was 1.92 (1.46 to 2.52)). Corresponding estimates in the population based analysis were similar (1.58 (1.51 to 1.65) for any stress related disorder, P=0.09 for difference between sibling and population based comparison, and 1.95 (1.66 to 2.28) for PTSD, P=0.92 for difference). Stress related disorders were associated with all studied life threatening infections, with the highest relative risk observed for meningitis (sibling based analysis 1.63 (1.23 to 2.16)) and endocarditis (1.57 (1.08 to 2.30)). Younger age at diagnosis of a stress related disorder and the presence of psychiatric comorbidity, especially substance use disorders, were associated with higher hazard ratios, whereas use of selective serotonin reuptake inhibitors in the first year after diagnosis of a stress related disorder was associated with attenuated hazard ratios. Conclusion In the Swedish population, stress related disorders were associated with a subsequent risk of life threatening infections, after controlling for familial background and physical or psychiatric comorbidities.
EP1.12-17 Neuroendocrine Marker Staining Pattern Categorization of Small-Sized Pulmonary Large Cell Neuroendocrine Carcinoma
Authors: K. Minami, Y. Tanaka, T. Okamoto, N. Shimizu, T. Doi, H. Ogawa, D. Hokka, N. Jimbo, W. Nishio, M. Yoshimura, T. Itoh, Y. Maniwa
Journal: Journal of Thoracic Oncology (2019)
P1.06-15 Safety of Irradiation Combined with Intracavitary Cisplatin-Fibrin After Lung-Sparing Surgery in a Rat Model of Mesothelioma
Authors: O. Lauk, M. Kirschner, M. Meerang, K. Furrer, I. Grgic, V. Orlowski, F. Tschanz, M. Pruschy, I. Opitz
Journal: Journal of Thoracic Oncology (2019)
MA11.10 Peripheral T Cell Repertoire Evolution in Resectable NSCLC Treated with Neoadjuvant PD-1 Blockade
Authors: J. Zhang, Z. Ji, J. Caushi, M. El Asmar, V. Anagnostou, T. Cottrell, H.Y. Chan, H. Guo, T. Merghoub, J. Chaft, J. Wolchok, J. Reuss, K. Marrone, J. Naidoo, E. Gabrielson, J. Taube, J. Brahmer, V. Velculescu, N. Zhao, M. Hellmann, P. Forde, D. Pardoll, S. Yegnasubramanian, H. Ji, K. Smith
Journal: Journal of Thoracic Oncology (2019)
Outcome of Patients Progressing or Relapsing after Primary Treatment with Two Cycles of Chemotherapy and Radiotherapy for Early Stage (Favorable) Hodgkin’s Disease.
Authors: Andreas Josting, Jeremy Franklin, Michal Sieniawski, Beate Pfistner, Thomas Schober, Hildtrud Nisters-Backes, Andreas Engert, Volker Diehl
Journal: Blood (2005)
P2.16-42 The Use of a Smartphone Application Improves Postoperative Outcomes in Patients Undergoing Lung Cancer Resection
Authors: C. Fraile Olivero, L. Milla Collado, J. Jarabo Sarceda, E. Fernández Martín, C. Cerdan Santacruz, J. Gastardi, A. Gómez Martínez, P. Arribas Manzanal, P. Santos Capa, M. Martínez Tardido, V. Alen, F. Hernando-Trancho
Journal: Journal of Thoracic Oncology (2019)
California’s medical board investigates doctors who write many vaccine exemptions
Authors: Owen Dyer
Journal: BMJ (2019)

A San Diego physician who writes hundreds of medical vaccination exemptions a year has become the third doctor to be charged with negligence over the practice by the Medical Board of California.

Tara Zandvliet failed to adequately document her claim of adverse medical history in exempting a young girl, the complaint against her alleges.

Also facing charges from the board is the paediatrician Robert Sears, a well known author whose books, written under the name “Dr Bob,” include his own alternative and selective vaccine schedules.

Zandvliet has granted 1000 exemptions since 2016, the complaint alleges. That year, California outlawed exemption requests that were based on a patient’s personal belief, and a doctor’s letter became the only legal way to avoid childhood …
OA10.05 Which Is Better for TNM Stage Assessment Among Whole-Body MRI and PET/MRI at 1.5 Tesla and 3 Tesla and FDG-PET/CT in Non-Small Cell Lung Cancer?
Authors: Y. Ohno, K. Aoyagi, M. Yui, D. Takenaka, T. Yoshikawa
Journal: Journal of Thoracic Oncology (2019)
Incidence and Risk Factors for IVIG-Mediated Hemolysis
Authors: Jacob Pendergrast, Beth Binnington, Tik Nga Tong, Jeannie Callum, Christine Margaret Cserti-Gazdewich, Wendy Lau, Lani Lieberman, Yulia Lin, Katerina Pavenski, Nadine Shehata, Rae Yeung, Donald R. Branch
Journal: Blood (2017)